The Carlton Hofferkamp & Jenks Wealth Management LLC Acquires Shares of 4,431 Amgen, Inc. (AMGN)

The Carlton Hofferkamp & Jenks Wealth Management LLC Acquires Shares of 4,431 Amgen, Inc. (AMGN)

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Thomas J. Herzfeld Advisors Inc. purchased a new position in Amgen during the fourth quarter valued at about $102,000. Focused Wealth Management Inc increased its position in Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock valued at $127,000 after buying an additional 620 shares in the last quarter. Northwest Quadrant Wealth Management LLC purchased a new position in Amgen during the fourth quarter valued at about $157,000. Cable Hill Partners LLC increased its position in Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock valued at $161,000 after buying an additional 26 shares in the last quarter. Finally, Cribstone Capital Management LLC increased its position in Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock valued at $182,000 after buying an additional 25 shares in the last quarter. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Carlton Hofferkamp & Jenks Wealth Management LLC acquired a new stake in Amgen, Inc. (NASDAQ:AMGN) during the first quarter, Holdings Channel reports. The institutional investor acquired 4,431 shares of the medical research company’s stock, valued at approximately $726,000.

Amgen, Inc. (AMGN) opened at 159.15 on Monday. The company has a market cap of $117.04 billion, a PE ratio of 15.12 and a beta of 1.15. Amgen, Inc. has a 12-month low of $133.64 and a 12-month high of $184.21. The firm’s 50-day moving average price is $159.96 and its 200-day moving average price is $159.70.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.15. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The firm had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the business earned $2.90 earnings per share. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. Equities research analysts forecast that Amgen, Inc. will post $12.45 earnings per share for the current fiscal year.

A number of research analysts have recently weighed in on AMGN shares. Robert W. Baird reissued a “neutral” rating and issued a $165.00 price target on shares of Amgen in a research note on Friday, March 17th. Cann reissued an “outperform” rating and issued a $189.00 price target on shares of Amgen in a research note on Tuesday, February 28th. Oppenheimer Holdings Inc. set a $175.00 price target on Amgen and gave the company a “buy” rating in a research note on Tuesday, February 14th. Credit Suisse Group AG reissued a “hold” rating and issued a $178.00 price target on shares of Amgen in a research note on Sunday, February 5th. Finally, Mizuho set a $195.00 price target on Amgen and gave the company a “buy” rating in a research note on Thursday, March 16th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $186.89. In other news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

About Amgen Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:AMGN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Related posts

Leave a Comment